<p>當你購買一家公司的股票時，總是存在價格跌至零的風險。另一方面，如果你找到一家高質量的企業進行投資（以合適的價格），你可以將資金翻倍！以 <strong>微創醫療</strong>（HKG:853）為例。其股價在過去十二個月中已經上漲了令人印象深刻的 149%。在過去一個季度，股價也上漲了 70%。該公司最近公佈了財務業績；你可以通過閲讀我們的公司報告來了解最新數據。不幸的是，從長期來看，回報並不理想，股票在過去三年中下跌了 1.5%。</p>
<p>由於長期表現良好，但最近回調了 3.7%，我們來檢查一下基本面是否與股價相符。</p>
<p>我們發現 21 只美國股票預計明年將支付超過 6% 的股息收益率。查看完整名單是免費的。</p>
<p>由於微創醫療在過去十二個月中出現了虧損，我們認為市場可能更關注收入和收入增長，至少目前是這樣。無盈利公司的股東通常希望看到強勁的收入增長。一些公司願意推遲盈利以更快地增長收入，但在這種情況下，人們希望看到良好的收入增長來彌補缺乏盈利。</p>
<p>在過去一年中，微創醫療的收入縮減了 0.7%。我們對股價在過去一年中上漲 149% 感到有些驚訝。這是一個很好的例子，説明買家如何在基本指標顯示出增長之前就推高價格。無論如何，收入下降很可能已經被市場定價。</p>
<p>下圖顯示了收益和收入隨時間的變化（如果你點擊圖像，可以看到更詳細的信息）。</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/26049405-earnings-and-revenue-growth-1-dark-2/1758320197908?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/26049405-earnings-and-revenue-growth-1-dark-2/1758320197908"/></p>
<p>SEHK:853 收益和收入增長 2025 年 9 月 19 日</p>
<p>看到在過去三個月中有一些顯著的內部人士購買是件好事。這是一個積極的信號。不過，我們認為收益和收入增長趨勢是更重要的考慮因素。因此，我們建議查看這份 <strong>免費的</strong> 報告，顯示共識預測。</p>
<h2>不同的視角</h2>
<p>我們很高興地報告，微創醫療的股東在一年內獲得了 149% 的總股東回報。這確實超過了過去五年每年約 9% 的損失。這讓我們有些警惕，但該業務可能已經扭轉了局面。雖然考慮市場條件對股價的不同影響是非常值得的，但還有其他因素更為重要。例如風險——微創醫療有 <strong>1 個警告信號</strong> 我們認為你應該注意。</p>
<p>微創醫療並不是唯一一家內部人士在購買的股票。因此，看看這份 <strong>免費的</strong> 小型公司名單，這些公司在吸引人的估值下被內部人士購買。</p>
<p><em>請注意，本文中引用的市場回報反映了目前在香港交易所交易的股票的市場加權平均回報。</em></p>

微創醫療

<p>微創醫療（HKG:853）的股東在過去一年中見證了股價的顯著增長，達到 149%，儘管最近出現了 9.7 億港元的下降。該股票在上個季度上漲了 70%，儘管過去一年收入下降了 0.7%。公司面臨挑戰，包括三年內下降了 1.5%，並且最近出現了虧損。過去三個月的內部人士買入是一個積極的信號，但由於潛在風險，建議保持謹慎。總體而言，該股票的表現引發了對其基本面的質疑</p>

<p>When you buy shares in a company, there is always a risk that the price drops to zero. On the other hand, if you find a high quality business to buy (at the right price) you can more than double your money! Take, for example <strong>MicroPort Scientific Corporation</strong> (HKG:853). Its share price is already up an impressive 149% in the last twelve months. It's also good to see the share price up 70% over the last quarter. The company reported its financial results recently; you can catch up on the latest numbers by reading our company report. Unfortunately the longer term returns are not so good, with the stock falling 1.5% in the last three years.</p>
<div class="lb-trans"><p>當你購買一家公司的股票時，總是存在價格跌至零的風險。另一方面，如果你找到一家高質量的企業進行投資（以合適的價格），你可以將資金翻倍！以 <strong>微創醫療</strong>（HKG:853）為例。其股價在過去十二個月中已經上漲了令人印象深刻的 149%。在過去一個季度，股價也上漲了 70%。該公司最近公佈了財務業績；你可以通過閲讀我們的公司報告來了解最新數據。不幸的是，從長期來看，回報並不理想，股票在過去三年中下跌了 1.5%。</p>
</div><p>Since the long term performance has been good but there's been a recent pullback of 3.7%, let's check if the fundamentals match the share price.</p>
<div class="lb-trans"><p>由於長期表現良好，但最近回調了 3.7%，我們來檢查一下基本面是否與股價相符。</p>
</div><p>We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.</p>
<div class="lb-trans"><p>我們發現 21 只美國股票預計明年將支付超過 6% 的股息收益率。查看完整名單是免費的。</p>
</div><p>Because MicroPort Scientific made a loss in the last twelve months, we think the market is probably more focussed on revenue and revenue growth, at least for now. Shareholders of unprofitable companies usually desire strong revenue growth. Some companies are willing to postpone profitability to grow revenue faster, but in that case one would hope for good top-line growth to make up for the lack of earnings.</p>
<div class="lb-trans"><p>由於微創醫療在過去十二個月中出現了虧損，我們認為市場可能更關注收入和收入增長，至少目前是這樣。無盈利公司的股東通常希望看到強勁的收入增長。一些公司願意推遲盈利以更快地增長收入，但在這種情況下，人們希望看到良好的收入增長來彌補缺乏盈利。</p>
</div><p>In the last year MicroPort Scientific saw its revenue shrink by 0.7%. We're a little surprised to see the share price pop 149% in the last year. This is a good example of how buyers can push up prices even before the fundamental metrics show much growth. It's quite likely the revenue fall was already priced in, anyway.</p>
<div class="lb-trans"><p>在過去一年中，微創醫療的收入縮減了 0.7%。我們對股價在過去一年中上漲 149% 感到有些驚訝。這是一個很好的例子，説明買家如何在基本指標顯示出增長之前就推高價格。無論如何，收入下降很可能已經被市場定價。</p>
</div><p>The image below shows how earnings and revenue have tracked over time (if you click on the image you can see greater detail).</p>
<div class="lb-trans"><p>下圖顯示了收益和收入隨時間的變化（如果你點擊圖像，可以看到更詳細的信息）。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/26049405-earnings-and-revenue-growth-1-dark-2/1758320197908" alt="" original-src="https://images.simplywall.st/asset/chart/26049405-earnings-and-revenue-growth-1-dark-2/1758320197908"/></p>
<p>SEHK:853 Earnings and Revenue Growth September 19th 2025</p>
<div class="lb-trans"><p>SEHK:853 收益和收入增長 2025 年 9 月 19 日</p>
</div><p>It's good to see that there was some significant insider buying in the last three months. That's a positive. That said, we think earnings and revenue growth trends are even more important factors to consider. So we recommend checking out this <strong>free</strong> report showing consensus forecasts</p>
<div class="lb-trans"><p>看到在過去三個月中有一些顯著的內部人士購買是件好事。這是一個積極的信號。不過，我們認為收益和收入增長趨勢是更重要的考慮因素。因此，我們建議查看這份 <strong>免費的</strong> 報告，顯示共識預測。</p>
</div><h2>A Different Perspective</h2>
<div class="lb-trans"><h2>不同的視角</h2>
</div><p>We're pleased to report that MicroPort Scientific shareholders have received a total shareholder return of 149% over one year. That certainly beats the loss of about 9% per year over the last half decade. This makes us a little wary, but the business might have turned around its fortunes. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. Take risks, for example - MicroPort Scientific has <strong>1 warning sign</strong> we think you should be aware of.</p>
<div class="lb-trans"><p>我們很高興地報告，微創醫療的股東在一年內獲得了 149% 的總股東回報。這確實超過了過去五年每年約 9% 的損失。這讓我們有些警惕，但該業務可能已經扭轉了局面。雖然考慮市場條件對股價的不同影響是非常值得的，但還有其他因素更為重要。例如風險——微創醫療有 <strong>1 個警告信號</strong> 我們認為你應該注意。</p>
</div><p>MicroPort Scientific is not the only stock insiders are buying. So take a peek at this <strong>free</strong> list of small cap companies at attractive valuations which insiders have been buying.</p>
<div class="lb-trans"><p>微創醫療並不是唯一一家內部人士在購買的股票。因此，看看這份 <strong>免費的</strong> 小型公司名單，這些公司在吸引人的估值下被內部人士購買。</p>
</div><p><em>Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Hong Kong exchanges.</em></p>
<div class="lb-trans"><p><em>請注意，本文中引用的市場回報反映了目前在香港交易所交易的股票的市場加權平均回報。</em></p>
</div>

儘管微創醫療（HKG:853）的市值在過去一週內縮水了 9.7 億港元，但其股東在一年內的收益仍然上漲了 149%